Shockwave Medical, Inc. SWAV recently announced the full U.S. commercial availability of the Shockwave L6 Peripheral Intravascular Lithotripsy (IVL) Catheter. This follows the receipt of the FDA’s ...
Johnson & Johnson MedTech’s Shockwave Medical has launched its Javelin Peripheral IVL Catheter in the US for peripheral artery disease (PAD). This new intravascular lithotripsy (IVL) platform is ...
On September 15, 2025, Johnson & Johnson (NYSE:JNJ) announced the European launch of its Shockwave Javelin Peripheral IVL Catheter, which is a groundbreaking platform to treat peripheral artery ...
SANTA CLARA, Calif., Oct. 19, 2023 (GLOBE NEWSWIRE) -- Shockwave Medical, Inc. (SWAV), a pioneer in the development and commercialization of transformational technologies for the treatment of ...
Physicians have a number of tools to treat coronary artery disease, the most common type of heart disease in the United States. But one breakthrough technology being offered at Catholic Medical Center ...
Shockwave Medical Inc., which is focused on intravascular lithotripsy (IVL) to treat severely calcified cardiovascular disease, saw its stock value rise Friday (NASDAQ:SWAV), eventually closing at $78 ...
Johnson & Johnson has announced the European launch of its Shockwave Javelin Peripheral IVL Catheter, an intravascular lithotripsy (IVL) platform aimed at addressing calcium buildup in severely ...
Shockwave Medical is moving to get its Intravascular Lithotripsy (IVL) technology approved in Japan. The Santa Clara-based company said it has initiated the DISRUPT CAD IV study of IVL in heavily ...
NEW BRUNSWICK, N.J. & SANTA CLARA, Calif.--(BUSINESS WIRE)--Johnson & Johnson (NYSE: JNJ) and Shockwave Medical, Inc. (Nasdaq: SWAV) (“Shockwave”) today announced that they have entered into a ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results